Veterinary Medicines

Avishield ND B1, lyophilisate for oculonasal suspension/use in drinking water for Chickens

Authorised
  • Newcastle disease virus, strain B1 Hitchner, Live
Download as PDF

Product identification

Medicine name:
Avishield ND B1, lyophilisate for oculonasal suspension/use in drinking water for Chickens
Avishield ND B1, lüofilisaat okulonasaalsuspensiooni valmistamiseks/joogivees manustamiseks kanadele
Active substance:
  • Newcastle disease virus, strain B1 Hitchner, Live
Target species:
  • Chicken
Route of administration:
  • Oculonasal use
  • Oral use

Product details

Active substance and strength:
  • Newcastle disease virus, strain B1 Hitchner, Live
    6.00
    log10 tissue culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate for oculonasal suspension/use in drinking water
Withdrawal period by route of administration:
  • Oculonasal use
    • Chicken
      • Meat and offal
        no withdrawal period
  • Oral use
    • Chicken
      • Meat and offal
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI01AD06
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Estonia
Package description:
  • Carton with 10 vials of 1000 doses of vaccine. Colourless glass vials (type I), which are closed with brombutyl rubber stoppers and sealed with aluminium caps.
  • Carton with 10 vials of 5000 doses of vaccine. Colourless glass vials (type I), which are closed with brombutyl rubber stoppers and sealed with aluminium caps.
  • Carton with 10 vials of 2500 doses of vaccine. Colourless glass vials (type I), which are closed with brombutyl rubber stoppers and sealed with aluminium caps.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Genera d.d.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Genera d.d.
Responsible authority:
  • State Agency Of Medicines
Authorisation number:
  • 2085
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0293/001
Concerned member states:
  • Austria
  • Belgium
  • Croatia
  • Czechia
  • Denmark
  • Estonia
  • France
  • Germany
  • Greece
  • Hungary
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Estonian (PDF)
Published on: 15/03/2022
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."